ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short Interest

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) saw a large decrease in short interest in April. As of April 30th, there was short interest totalling 3,160,000 shares, a decrease of 14.4% from the April 15th total of 3,690,000 shares. Based on an average trading volume of 521,400 shares, the short-interest ratio is currently 6.1 days. Currently, 11.5% of the company's stock are sold short.

Insiders Place Their Bets

In other news, insider Jaume Pons sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the sale, the insider now owns 628,359 shares of the company's stock, valued at approximately $7,006,202.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Jaume Pons sold 20,000 shares of the business's stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the transaction, the insider now directly owns 628,359 shares of the company's stock, valued at approximately $7,006,202.85. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jason Lettmann acquired 4,400 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was purchased at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the transaction, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The disclosure for this purchase can be found here. Insiders have sold a total of 90,000 shares of company stock worth $1,251,400 in the last three months. Corporate insiders own 33.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. abrdn plc acquired a new position in ALX Oncology in the 4th quarter worth about $986,000. China Universal Asset Management Co. Ltd. grew its stake in ALX Oncology by 445.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company's stock valued at $86,000 after acquiring an additional 4,706 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in ALX Oncology during the fourth quarter worth $28,000. Hsbc Holdings PLC purchased a new position in ALX Oncology during the third quarter valued at $168,000. Finally, SG Americas Securities LLC grew its position in shares of ALX Oncology by 201.4% in the fourth quarter. SG Americas Securities LLC now owns 30,348 shares of the company's stock valued at $452,000 after purchasing an additional 20,279 shares during the period. Institutional investors and hedge funds own 97.97% of the company's stock.

ALX Oncology Stock Performance

NASDAQ:ALXO traded down $0.44 during mid-day trading on Tuesday, hitting $15.17. The company's stock had a trading volume of 385,282 shares, compared to its average volume of 456,772. The business's fifty day moving average is $13.83 and its two-hundred day moving average is $12.99. The stock has a market cap of $790.36 million, a price-to-earnings ratio of -4.13 and a beta of 1.30. ALX Oncology has a 1 year low of $3.94 and a 1 year high of $17.83. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Analysts anticipate that ALX Oncology will post -3.33 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Stifel Nicolaus reiterated a "hold" rating and issued a $14.00 price target (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research note on Friday, April 12th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.